Anti-Human OX40L (Oxelumab) – Dylight® 488
Anti-Human OX40L (Oxelumab) – Dylight® 488
Product No.: LT1311
- -
- -
Product No.LT1311 Clone R4930 Target TNFSF4 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names TNFSF4; GP34; CD252; TXGP1; CD134L; TNLG2B Isotype Human IgG1κ Applications FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Original antibody raised against Human OX40L Product Concentration 0.2 mg/ml Formulation This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Blue Laser (493 nm) RRIDAB_2893902 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Oxelumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Oxelumab. Clone R4930 binds to Human OX40L (TNFSF4). This product is for research use only. Background Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L (TNFSF4). OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L (Oxelumab) utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects. Antigen Distribution OX40L is expressed in various cell types including antigen presenting cells, T-cells, vascular endothelial cells, mast cells, and natural killer cells. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Costimulatory Molecules . Immuno-Oncology . Immunology References & Citations1. Mahmood,T. and Yang, P. (2012) N Am J Med Sci. 4(11): 533–536 2. Spicer, P. and Runkel, L. (2019) Expert Opin Investig Drugs. 28(2):99-106 3. Heo, YS. et al. (2014) Bio Design 2(2):55-61 Technical ProtocolsFA  Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT1300 | |
LT1303 | |
LT1304 | |
LT1311 | |
LT1305 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.